cholinergic urticaria: a type of physical urticarias (or hives) that appears when a person is sweating.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
183 |
4. Check minimum number of eventsNone |
183 |
5. Include endpointsNone |
183 |
6. Filter based on genotype QC (FinnGen only) |
183 |
Control definitions (FinnGen only)
- Control exclude
- L12_URTICARIAERYTHEMA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L50
- Name in latin
- Urticaria cholinergica
Similar endpoints
↥List of similar endpoints to
Cholinergic urticaria
based on the number of shared cases.
Similar with more cases:
- Urticaria
- Urticaria and erythema
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1274 | 625 | 643 |
| Only index persons | 1222 | 606 | 616 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 28.90 | 35.86 | 22.06 |
| Only index persons | 28.80 | 35.69 | 22.03 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 183 | 113 | 70 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.03 |
| Median age at first event (years) | 37.77 | 43.73 | 28.14 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 170
- Matched controls
- 1701
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L50.5
ICD-10 Finland
Cholinergic urticaria
+∞
201.6
151
*
L50.3
ICD-10 Finland
Dermatographic urticaria
156.4
36.3
37
*
L50.0
ICD-10 Finland
Allergic urticaria
60.2
26.2
30
6
R06AE09
ATC
levocetirizine; oral
6.8
23.5
69
155
C01CA24
ATC
epinephrine; parenteral
13.9
23.3
41
38
XQ800
NOMESCO Finland
Prick test
9.4
21.5
47
66
L50.8
ICD-10 Finland
Other urticaria
87.8
21.3
23
*
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
8.4
21.2
50
80
L50.9
ICD-10 Finland
Urticaria, unspecified
24.7
20.8
29
14
L50.2
ICD-10 Finland
Urticaria due to cold and heat
+∞
20.2
19
*
R06AE07
ATC
cetirizine; oral
4.7
19.8
120
573
R03DC03
ATC
montelukast; oral
5.6
18.6
63
162
7085A
ICD-9 Finland
Urticaria, Cholinergic urticaria
+∞
18.0
17
*
L50.1
ICD-10 Finland
Idiopathic urticaria
+∞
17.0
16
*
R06AX27
ATC
desloratadine; oral
4.2
16.5
87
341
H02AB06
ATC
prednisolone; systemic
3.7
14.8
101
481
R06AX22
ATC
ebastine; oral
4.2
13.5
59
189
T78.4
ICD-10 Finland
Allergy, unspecified
9.3
11.2
23
28
XQ810
NOMESCO Finland
Physical test for urticaria
+∞
10.5
10
*
R06AX13
ATC
loratadine; oral
3.7
10.0
48
163
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
3.6
10.0
52
187
J45.0
ICD-10 Finland
Predominantly allergic asthma
5.0
9.2
30
70
D07AB02
ATC
hydrocortisone butyrate; topical
3.0
9.0
65
293
L20.0
ICD-10 Finland
Besnier prurigo
5.5
8.8
26
54
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
21.4
8.6
12
6
D07AB08
ATC
desonide; topical
4.5
8.5
31
81
E0000UV
ATC
NA
2.6
8.3
84
461
N05BB01
ATC
hydroxyzine; systemic
5.3
8.0
24
51
E000001
ATC
NA
3.0
7.8
50
207
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
3.4
7.2
36
124
L50
ICD-10 Finland
Urticaria
14.6
7.0
11
8
J45
ICD-10 Finland
Asthma
3.9
6.9
28
81
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.4
6.4
71
395
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
18.9
6.3
9
5
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.4
6.2
68
375
R06AX26
ATC
fexofenadine; oral
4.2
6.1
22
58
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
87
557
2.07
5.47
4.2
6.3
1.2
1.2
mmol/l
0.73
79
516
11
24
4.81
4.85
1.9
4.8
50.9
59.1
%
0.86
11
24
71
443
1.98
4.63
2.5
2.8
—
—
—
0
0
141
1118
2.14
4.52
5.7
3.7
10.7
9.7
mm/h
0.27
133
1039
59
348
2.03
4.48
2.8
2.6
0.1
0.2
e6/l
1.32
47
250
76
495
1.92
4.30
2.0
1.8
94.6
96.3
pmol/l
0.13
35
259
37
185
2.25
4.27
2.2
3.9
0.8
0.8
mmol/l
0.23
31
174
62
382
1.94
4.11
1.8
1.6
—
—
—
0
0
24
102
2.56
3.94
1.2
1.2
95.3
144.4
iu/ml
—
6
45
88
614
1.83
3.93
5.0
7.2
1.2
1.2
mmol/l
0.36
75
522
91
662
1.75
3.39
3.0
2.6
148.2
93.6
ug/l
0.47
85
623
34
182
2.07
3.29
2.0
2.5
2.8
3.3
e6/l
0.11
20
87
138
1147
1.83
3.07
5.1
3.8
15.0
14.5
pmol/l
1.66
128
1054
36
202
1.97
3.06
1.9
2.4
0.3
0.9
e6/l
2.46
22
107
45
274
1.85
3.00
1.5
1.4
21.8
21.8
nmol/l
0.00
33
241
110
873
1.65
2.75
9.3
9.5
3.6
4.0
e9/l
1.29
103
765
76
550
1.65
2.73
2.8
2.2
74.9
75.1
nmol/l
0.02
69
506
44
275
1.79
2.68
1.3
1.3
12.0
24.8
iu/ml
1.62
16
100
32
183
1.91
2.57
1.7
2.2
2.3
2.5
g/l
1.04
26
169
11
39
2.94
2.52
1.0
1.2
3.4
3.8
mmol/l
1.23
11
34
9
26
3.59
2.52
1.1
1.1
—
—
—
0
0
48
314
1.72
2.49
1.8
1.6
0.8
1.0
mg/l
0.47
30
242
156
1380
1.88
2.42
6.0
4.4
1.6
2.7
mu/l
0.66
149
1277
168
1531
2.19
2.27
13.9
11.7
13.3
20.5
mg/l
3.57
124
1171
62
448
1.58
2.16
4.0
3.3
2.4
2.4
mmol/l
0.03
49
396
18
89
2.13
2.14
1.1
1.0
—
—
—
0
0
11
43
2.66
2.14
1.2
1.2
—
—
—
0
0
66
485
1.56
2.13
3.3
3.4
29.2
22.4
ng/l
0.23
38
286
53
370
1.61
2.12
1.6
1.2
3.1
1.5
u/ml
—
9
107
29
175
1.78
1.98
1.9
2.2
21.9
24.3
%
0.54
24
147
40
267
1.64
1.91
1.4
1.2
1.2
10.3
u/ml
2.12
18
110
51
362
1.57
1.89
1.7
1.7
1.2
1.4
mmol/l
1.59
39
313
11
46
2.48
1.89
2.3
1.5
—
—
—
0
0
9
35
2.65
1.83
2.2
2.4
147.8
166.7
%
—
9
35
147
1311
1.62
1.81
17.8
14.1
13.3
13.5
%
2.04
147
1292
10
42
2.46
1.71
1.2
1.2
—
—
—
0
0
65
499
1.47
1.65
3.1
3.0
32.3
32.0
u/l
0.02
58
472
34
226
1.62
1.65
3.2
3.2
265.8
513.3
ng/l
0.27
24
150
5
15
3.40
1.53
1.2
1.1
—
—
—
0
0
5
15
3.40
1.53
1.2
1.1
—
—
—
0
0
5
15
3.40
1.53
1.2
1.1
—
—
—
0
0
5
15
3.40
1.53
1.2
1.1
—
—
—
0
0
5
15
3.40
1.53
1.2
1.1
—
—
—
0
0
70
552
1.43
1.53
4.5
4.6
37.9
36.7
g/l
1.45
63
524
86
705
1.41
1.51
4.6
4.6
0.0
0.0
estimate
0.00
23
136
86
705
1.41
1.51
3.3
3.2
0.0
0.0
estimate
0.00
23
135
37
257
1.55
1.50
2.4
2.3
—
—
—
0
0
11
52
2.19
1.47
1.8
1.7
—
—
—
0
0
131
1164
1.44
1.41
3.2
3.4
—
—
—
0
0
5
17
2.99
1.37
1.4
1.4
—
—
—
0
0
0
38
0.00
1.36
0.0
1.6
—
—
—
0
0
0
38
0.00
1.36
0.0
1.6
—
—
—
0
0
160
1486
1.61
1.32
16.6
12.1
40.4
40.8
%
0.27
127
1176
9
43
2.15
1.32
4.2
2.9
—
—
—
0
0
8
34
2.41
1.31
1.4
1.2
—
—
—
0
0
70
567
1.38
1.27
3.2
3.3
—
—
—
0
0
5
19
2.68
1.22
1.0
1.1
—
—
—
0
0
38
278
1.46
1.21
2.3
1.9
2.5
3.2
mg/l
1.49
31
246
85
715
1.35
1.21
3.3
3.3
0.0
0.0
estimate
0.00
21
131
171
1622
1.83
1.21
12.4
9.3
25.2
27.6
u/l
1.74
165
1575
41
307
1.43
1.16
1.7
2.3
—
—
—
0
0
5
20
2.54
1.16
1.0
1.1
—
—
—
0
0
5
20
2.54
1.16
3.8
5.5
367.8
360.9
umol/l
—
5
15
5
21
2.42
1.10
1.0
1.1
—
—
—
0
0
14
83
1.74
1.05
1.1
1.4
—
—
—
0
0
91
787
1.31
1.02
3.8
4.8
6.4
6.4
mmol/l
0.07
86
714
123
1110
1.33
1.01
3.3
2.9
37.8
41.9
u/l
0.42
116
1060
5
23
2.21
0.98
1.2
1.4
—
—
—
0
0
9
50
1.84
0.98
1.3
2.3
—
—
—
0
0
44
345
1.36
0.96
2.8
2.7
335.1
2255.7
umol/l
0.80
38
306
48
382
1.35
0.95
3.3
3.3
0.0
0.0
estimate
0.00
21
135
19
127
1.55
0.93
2.6
4.2
258.3
236.8
u/l
0.18
19
121
6
28
2.18
0.92
1.0
1.7
—
—
—
0
0
8
44
1.85
0.87
1.0
1.1
—
1.2
—
0
7
28
210
1.39
0.80
2.0
2.7
2.4
2.4
mmol/l
0.40
21
180
6
33
1.85
0.80
1.8
2.5
—
—
—
0
0
0
25
0.00
0.79
0.0
1.4
—
—
—
0
0
0
27
0.00
0.78
0.0
1.6
—
—
—
0
0
6
34
1.79
0.77
1.0
1.1
—
—
—
0
0
0
28
0.00
0.76
0.0
1.4
—
—
—
0
0
14
204
0.66
0.73
1.5
1.9
—
—
—
0
0
30
232
1.35
0.72
2.2
2.1
—
—
—
0
0
5
28
1.81
0.66
2.2
1.6
—
—
—
0
0
39
318
1.29
0.66
2.5
3.0
743.4
881.8
ng/l
0.22
27
263
27
209
1.34
0.65
2.0
1.6
1120.5
1215.4
nmol/l
0.26
20
161
5
30
1.68
0.62
1.4
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.4
—
—
—
0
0
0
20
0.00
0.60
0.0
1.9
—
—
—
0
0
11
72
1.56
0.60
1.9
1.5
—
—
—
0
0
0
21
0.00
0.60
0.0
1.4
—
—
—
0
0
10
64
1.60
0.60
4.0
4.8
25.5
25.6
mmol/l
—
10
64
8
53
1.53
0.59
1.8
1.4
—
—
—
0
0
8
54
1.50
0.58
1.4
1.1
—
—
—
0
0
6
37
1.64
0.56
1.0
1.1
—
—
—
0
0
147
1403
1.24
0.52
15.0
10.1
90.2
88.2
ml/min/173m2
0.49
122
1117
10
143
0.68
0.50
1.5
1.7
—
—
—
0
0
7
47
1.51
0.48
2.0
1.5
—
—
—
0
0
5
84
0.58
0.46
3.4
12.3
25.3
24.5
mmol/l
—
5
79
7
49
1.45
0.46
1.1
1.1
—
—
—
0
0
10
140
0.70
0.45
1.5
1.6
—
—
—
0
0
5
33
1.53
0.41
2.2
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
2.1
—
—
—
0
0
0
15
0.00
0.41
0.0
2.1
—
—
—
0
0
0
15
0.00
0.41
0.0
2.1
—
—
—
0
0
0
17
0.00
0.41
0.0
2.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
29
244
1.22
0.39
5.0
4.2
19.0
21.3
%
0.40
12
99
16
127
1.28
0.35
4.3
2.9
—
—
—
0
0
22
186
1.21
0.29
1.3
1.7
—
—
—
0
0
10
78
1.30
0.24
1.4
1.6
—
—
—
0
0
153
1494
1.15
0.24
4.3
3.9
1.4
1.5
mmol/l
0.69
145
1393
10
125
0.79
0.23
3.1
10.6
14.5
12.5
kpa
—
10
118
10
125
0.79
0.23
3.1
10.6
5.0
5.1
kpa
—
10
118
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
3.0
—
0
7
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
14
0.00
0.20
0.0
3.4
—
875.1
—
0
14
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
6
49
1.23
0.20
2.3
1.6
—
—
—
0
0
148
1448
1.12
0.19
3.7
3.6
1.3
1.3
mmol/l
0.14
139
1345
153
1500
1.12
0.19
4.2
4.0
4.8
4.8
mmol/l
0.02
146
1408
12
141
0.84
0.17
4.3
2.0
—
—
—
0
0
6
79
0.75
0.16
3.0
3.4
5.4
5.1
kpa
—
6
74
155
1525
1.11
0.15
4.8
4.3
2.9
2.8
mmol/l
0.48
146
1423
15
170
0.87
0.14
4.3
6.1
—
—
—
0
0
137
1344
1.08
0.13
5.3
5.0
38.4
38.8
mmol/mol
0.22
129
1277
69
664
1.06
0.12
3.0
4.1
—
—
—
0
0
33
309
1.08
0.11
1.3
1.4
—
—
—
0
0
145
1432
1.06
0.08
4.8
3.9
5.7
5.8
mmol/l
0.41
133
1339
7
65
1.08
0.08
1.6
1.7
—
—
—
0
0
6
70
0.85
0.08
2.0
1.3
—
—
—
0
0
12
108
1.12
0.07
3.8
2.0
—
—
—
0
0
14
151
0.92
0.05
3.4
4.2
33.1
30.8
%
—
8
103
14
131
1.07
0.03
3.4
1.8
370.1
387.7
nmol/l
0.19
14
118
11
108
1.02
0.00
2.9
11.8
129.0
124.8
g/l
0.33
11
103
5
58
0.86
0.00
1.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
5
57
0.87
0.00
1.4
3.6
55.0
51.2
%
—
5
57
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
2.7
—
—
—
0
0
9
92
0.98
0.00
2.0
1.5
—
—
—
0
0
6
67
0.89
0.00
1.7
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
0.00
1.2
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_URTICA_CHOLINERG and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have L12_URTICA_CHOLINERG.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: L12_URTICA_CHOLINERG – Cholinergic urticaria
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data